MacroGenics (MGNX) Hisse Özeti
Klinik aşamada bir biyofarmasötik şirketi olan MacroGenics, Inc. Amerika Birleşik Devletleri'nde kanser tedavisi için antikor bazlı terapötikleri keşfetmekte, geliştirmekte, üretmekte ve ticarileştirmektedir. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 2/6 |
| Gelecekteki Büyüme | 0/6 |
| Geçmiş Performans | 0/6 |
| Finansal Sağlık | 6/6 |
| Temettüler | 0/6 |
MGNX Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
MacroGenics, Inc. Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$3.92 |
| 52 Haftanın En Yüksek Seviyesi | US$5.08 |
| 52 Haftanın En Düşük Seviyesi | US$1.29 |
| Beta | 1.22 |
| 1 Aylık Değişim | -9.47% |
| 3 Aylık Değişim | 13.62% |
| 1 Yıllık Değişim | 166.67% |
| 3 Yıllık Değişim | -26.87% |
| 5 Yıllık Değişim | -83.57% |
| Halka arzdan bu yana değişim | -84.31% |
Son Haberler & Güncellemeler
Seeking Alpha • Jul 27
MacroGenics: Whipsaws On Clinical Data, But The Big Picture Is Still Important
Summary MacroGenics is affirmed as a 'Buy' due to a de-risked operational runway and promising B7-H3 ADC pipeline asset. MGNX's pipeline is refocused after setbacks; cash infusions and divestitures extend the runway through 2028, trading near liquid value. MGC026, the B7-H3 ADC, shows no major safety issues and will present data in late 2026, offering potential upside if efficacy emerges. Despite market skepticism from past failures, MGNX could benefit from sector tailwinds if B7-H3 ADCs gain traction following Daiichi Sankyo's progress. Read the full article on Seeking Alpha
Anlatı Güncellemesi • Jun 23
MGNX: Tubulus Deal Optimism Will Likely Outpace Real Execution Progress
Analysts have raised their price target on MacroGenics by $2, citing updated assumptions regarding fair value, discount rate, revenue growth, profit margin, and future P/E following recent research and deal commentary. Analyst Commentary Recent research on MacroGenics reflects a mix of interest in the story and caution around what is already priced into the stock.Recent updates
Seeking Alpha • Jul 27
MacroGenics: Whipsaws On Clinical Data, But The Big Picture Is Still Important
Summary MacroGenics is affirmed as a 'Buy' due to a de-risked operational runway and promising B7-H3 ADC pipeline asset. MGNX's pipeline is refocused after setbacks; cash infusions and divestitures extend the runway through 2028, trading near liquid value. MGC026, the B7-H3 ADC, shows no major safety issues and will present data in late 2026, offering potential upside if efficacy emerges. Despite market skepticism from past failures, MGNX could benefit from sector tailwinds if B7-H3 ADCs gain traction following Daiichi Sankyo's progress. Read the full article on Seeking AlphaAnlatı Güncellemesi • Jun 23
MGNX: Tubulus Deal Optimism Will Likely Outpace Real Execution Progress
Analysts have raised their price target on MacroGenics by $2, citing updated assumptions regarding fair value, discount rate, revenue growth, profit margin, and future P/E following recent research and deal commentary. Analyst Commentary Recent research on MacroGenics reflects a mix of interest in the story and caution around what is already priced into the stock.
Anlatı Güncellemesi • Jun 05
MGNX: Antibody Drug Conjugate Data And Deals Will Drive Future Upside
Narrative Update: MacroGenics Analysts have raised their price targets on MacroGenics by $1 to $2, citing updated views on the company's antibody drug conjugate potential and recent deal activity as key reasons for the higher valuation outlook. Analyst Commentary Recent Street research on MacroGenics has focused on price target changes, rating shifts and the role of the antibody drug conjugate pipeline in shaping expectations for future execution and potential valuation outcomes.Anlatı Güncellemesi • May 21
MGNX: Antibody Drug Conjugate Progress Will Drive Future Upside Potential
Analysts have lifted their price target on MacroGenics to $6.75 from $3.75, citing updated assumptions on revenue trends, profitability and a lower expected P/E multiple, as well as recent positive research following the Tubulis deal and ongoing antibody drug conjugate progress. Analyst Commentary Bullish Takeaways Bullish analysts point to the higher price targets as a reflection of updated assumptions on revenue trends and profitability, suggesting they see the current valuation as more aligned with their revised models.
Anlatı Güncellemesi • Apr 26
MGNX: Antibody Drug Conjugate Pipeline And 2026 Data Will Drive Repricing
Narrative Update on MacroGenics Analysts have raised their price targets on MacroGenics by $2 to $4. They cite updated revenue assumptions and interest in the company’s antibody drug conjugate pipeline as key factors behind the change.Anlatı Güncellemesi • Apr 12
MGNX: Antibody Drug Conjugate Pipeline And Tubulus Deal Will Drive Repricing
Analysts raised their price target for MacroGenics from $5.00 to $9.00, citing updated assumptions for potential revenue growth, slightly higher profit margins, a lower discount rate and recent positive sentiment following the Tubulus deal and the outlook for antibody-drug conjugate data. Analyst Commentary Bullish analysts are pointing to recent research updates as a sign that expectations for MacroGenics are shifting toward a more constructive view, with price targets and ratings adjusted to reflect changing assumptions around future execution and potential revenue streams.Analiz Makalesi • Jan 06
There's No Escaping MacroGenics, Inc.'s (NASDAQ:MGNX) Muted Revenues Despite A 26% Share Price Rise
MacroGenics, Inc. ( NASDAQ:MGNX ) shareholders are no doubt pleased to see that the share price has bounced 26% in the...Anlatı Güncellemesi • Sep 25
LORIKEET And LINNET Trials Will Spur Advances Amid Liquidity Risks
The consensus analyst price target for MacroGenics increased to $3.75, primarily reflecting a higher expected future P/E multiple despite a decline in net profit margin. What's in the News Eric Risser appointed Chief Executive Officer, succeeding long-time CEO Scott Koenig; Risser has extensive company and industry experience, having led corporate development efforts that generated $1.6 billion in non-dilutive capital.Analiz Makalesi • Sep 08
MacroGenics, Inc.'s (NASDAQ:MGNX) Share Price Boosted 30% But Its Business Prospects Need A Lift Too
MacroGenics, Inc. ( NASDAQ:MGNX ) shareholders would be excited to see that the share price has had a great month...Anlatı Güncellemesi • Aug 16
LORIKEET And LINNET Trials Will Spur Advances Amid Liquidity Risks
Despite an improving net profit margin and a sharply lower future P/E multiple reflecting more attractive valuation, the consensus analyst price target for MacroGenics has been notably reduced from $4.20 to $3.40. What's in the News Eric Risser appointed CEO, succeeding longtime leader Scott Koenig; Risser brings significant operational and business development experience, including generating over $1.6 billion in non-dilutive capital for the company.Analiz Makalesi • Jul 24
MacroGenics, Inc. (NASDAQ:MGNX) Surges 37% Yet Its Low P/S Is No Reason For Excitement
MacroGenics, Inc. ( NASDAQ:MGNX ) shares have had a really impressive month, gaining 37% after a shaky period...Analiz Makalesi • May 21
Analyst Forecasts For MacroGenics, Inc. (NASDAQ:MGNX) Are Surging Higher
MacroGenics, Inc. ( NASDAQ:MGNX ) shareholders will have a reason to smile today, with the analysts making substantial...Analiz Makalesi • Apr 14
MacroGenics, Inc. (NASDAQ:MGNX) Looks Inexpensive After Falling 42% But Perhaps Not Attractive Enough
Unfortunately for some shareholders, the MacroGenics, Inc. ( NASDAQ:MGNX ) share price has dived 42% in the last thirty...
Yeni Anlatı • Apr 02
LORIKEET And LINNET Trials Will Spur Advances Amid Liquidity Risks
Future revenue growth potential hinges on successful trial outcomes and product approvals in ongoing and upcoming clinical studies.Analiz Makalesi • Feb 28
MacroGenics, Inc. (NASDAQ:MGNX) Not Doing Enough For Some Investors As Its Shares Slump 26%
Unfortunately for some shareholders, the MacroGenics, Inc. ( NASDAQ:MGNX ) share price has dived 26% in the last thirty...Seeking Alpha • Feb 27
MacroGenics: Stacking Up A Lot Of Headwinds... But It's Fallen Too Far
Summary MacroGenics' valuation has declined due to continued bad news in 2024, impacting market sentiment. MGNX holds $179.6M in cash and equivalents, with a sustainable cash burn rate for up to 5 years. Sale of the margetuximab franchise poises the company for further financial stability. Operating expenses are expected to rise as clinical programs advance, with management projecting a cash runway into 2026. I think this is a conservative estimate. Although a lot has changed, I think these price levels are attractive for a tentative investment based on catalysts I anticipate in 2025 and beyond. Read the full article on Seeking AlphaSeeking Alpha • Dec 05
MacroGenics: A Productive Biotech With Growing Potential - Still Not A Buy
Summary MacroGenix was previously rated as a "Hold" due to uncertain revenue streams and high annual expenses of ~$300 million. Since the initial rating, MacroGenix's stock has dropped approximately 33%, reflecting ongoing financial challenges. The company's reliance on episodic milestones and minimal product revenues makes it unattractive for new investors. Existing investors might accept the risk, but the current financial outlook remains unattractive for prospective buyers. Read the full article on Seeking AlphaAnaliz Makalesi • Aug 01
Party Time: Brokers Just Made Major Increases To Their MacroGenics, Inc. (NASDAQ:MGNX) Earnings Forecasts
MacroGenics, Inc. ( NASDAQ:MGNX ) shareholders will have a reason to smile today, with the analysts making substantial...Analiz Makalesi • Jul 30
MacroGenics, Inc.'s (NASDAQ:MGNX) Share Price Boosted 29% But Its Business Prospects Need A Lift Too
MacroGenics, Inc. ( NASDAQ:MGNX ) shareholders are no doubt pleased to see that the share price has bounced 29% in the...Analiz Makalesi • Jul 12
We're A Little Worried About MacroGenics' (NASDAQ:MGNX) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Analiz Makalesi • May 13
MacroGenics, Inc.'s (NASDAQ:MGNX) 81% Dip In Price Shows Sentiment Is Matching Revenues
MacroGenics, Inc. ( NASDAQ:MGNX ) shareholders that were waiting for something to happen have been dealt a blow with a...Seeking Alpha • May 13
MacroGenics: Strong Likelihood Bad News Has Caused Overreaction (Rating Upgrade)
Summary Macrogenics' stock valuation has dropped over 70% after its first quarter update, creating a new opportunity for investors. The spotlight is on their product vobramitamab duocarmazine, and the phase 2 TAMARACK trial. Macrogenics has between 4 and 5 quarters of cash and investments on hand. Read the full article on Seeking AlphaSeeking Alpha • Apr 05
MacroGenics: Positive Safety Update Leads To Two Major Inflection Points In 2024
Summary Positive safety update released from phase 2 TAMARACK study, using vobra duo for the treatment of patients with metastatic castration-resistant prostate cancer. Updates to interim data from the phase 2 TAMARACK study expected by May 31st of 2024. Radiographic progression-free survival data from the phase 2 TAMARACK study, expected by fall of 2024. The global prostate cancer market size is estimated to reach $27.51 billion by 2032. Read the full article on Seeking AlphaAnaliz Makalesi • Feb 28
MacroGenics, Inc. (NASDAQ:MGNX) Surges 27% Yet Its Low P/S Is No Reason For Excitement
Despite an already strong run, MacroGenics, Inc. ( NASDAQ:MGNX ) shares have been powering on, with a gain of 27% in...Seeking Alpha • Feb 15
MacroGenics: Trying To Build A Better Everything
Summary MacroGenics, Inc. has a pipeline of promising drugs including Vobramitamab Duocarmazine, Lorigerlimab, Tebotelimab, MGD024, and IMGC936. The company has a strong financial position as of their latest report. MacroGenics faces both strengths and risks in their drug development and commercialization efforts. Read the full article on Seeking AlphaHissedar Getirileri
| MGNX | US Biotechs | US Pazar | |
|---|---|---|---|
| 7D | 0.5% | 4.9% | 0.09% |
| 1Y | 166.7% | 41.3% | 19.0% |
Getiri vs. Endüstri: MGNX geçen yıl % 41.3 oranında getiri sağlayan US Biotechs sektörünü aştı.
Getiri vs Piyasa: MGNX geçen yıl % 19 oranında getiri sağlayan US Piyasasını aştı.
Fiyat Oynaklığı
| MGNX volatility | |
|---|---|
| MGNX Average Weekly Movement | 12.0% |
| Biotechs Industry Average Movement | 10.1% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
İstikrarlı Hisse Senedi Fiyatı: MGNX hisse senedi fiyatı, son 3 ayda US piyasasına kıyasla dalgalı seyretti.
Zaman İçindeki Volatilite: MGNX 'nin haftalık oynaklığı ( 12% ) geçen yıl boyunca sabit kaldı, ancak hala US hisselerinin %75'inden yüksek.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 2000 | 293 | Eric Risser | www.macrogenics.com |
Klinik aşamada bir biyofarmasötik şirketi olan MacroGenics, Inc. ABD'de kanser tedavisi için antikor bazlı terapötikleri keşfetmekte, geliştirmekte, üretmekte ve ticarileştirmektedir. Şirketin ürün hattı, faz 2 klinik çalışmalarında olan mCRPC ve docetaxel tedavisi için kontrol noktası inhibitörleri PD-1 ve CTLA-4'ü hedefleyen bispesifik bir DART molekülü olan lorigerlimab'ın yanı sıra platine dirençli yumurtalık kanseri ve faz 1 klinik çalışmasını tamamlayan berrak hücreli jinekolojik kanser tedavisini içermektedir; MGC026, B7-H3'ü hedefleyen ve yeni bir topoizomeraz I inhibitörü (TOP1i) tabanlı bağlantı yükü sağlayan bir ADC; MGC028, ADAM9'u hedefleyen ve faz 1 klinik çalışmalarında olan katı tümörlerin tedavisi için yeni bir TOP1i tabanlı bağlantı yükü sağlayan bir antikor-ilaç konjugatları (ADC); MGC030, preklinik çalışmalarda olan çeşitli katı tümörlerde ifade edilen açıklanmayan bir antijeni hedefleyen bir ADC molekülü. Ayrıca T-hücresi çekici programları da geliştirmektedir.
MacroGenics, Inc. Temel Bilgiler Özeti
| MGNX temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$259.34m |
| Kazançlar(TTM) | -US$70.36m |
| Gelir(TTM) | US$157.08m |
1.6x
P/S Oranı-3.5x
F/K OranıMGNX aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| MGNX gelir tablosu (TTM) | |
|---|---|
| Gelir | US$157.08m |
| Gelir Maliyeti | US$182.59m |
| Brüt Kâr | -US$25.50m |
| Diğer Giderler | US$44.85m |
| Kazançlar | -US$70.36m |
Son Raporlanan Kazançlar
Mar 31, 2026
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | -1.11 |
| Brüt Marj | -16.24% |
| Net Kâr Marjı | -44.79% |
| Borç/Özkaynak Oranı | 0% |
MGNX uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/08/11 14:26 |
| Gün Sonu Hisse Fiyatı | 2026/08/11 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
MacroGenics, Inc. 18 Bu analistlerden 5, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Peter Lawson | Barclays |
| Etzer Darout | Barclays |
| Stephen V. Byrne | BofA Global Research |